Safety of an Abbreviated Transition Period When Switching From Intravenous Immunoglobulin to Eculizumab in Patients with Treatment-Refractory Myasthenia Gravis: A Case Series

DOI: 10.12659/AJCR.916424

Keywords: Complement Inactivating Agents, Immunoglobulins, Intravenous, Myasthenia Gravis

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text